Ratings Abbott India Limited NSE India S.E.

Equities

Market Closed - NSE India S.E. Other stock markets 05:10:46 16/05/2024 pm IST			5-day change	1st Jan Change
26,543 ^INR	+0.50%		+2.34%	+16.15%

10/05	Abbott India's Net Profit Climbs in Fiscal Q4; Shares Up 3%	MT
09/05	Drugmaker Abbott India posts Q4 profit rise on higher sales	RE

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.3 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

	1st Jan change	Capi.	ESG Refinitiv
ABBOTT INDIA LIMITED	+16.15%	6.73B	-
ELI LILLY AND COMPANY	+33.15%	709B	C+
NOVO NORDISK A/S	+30.77%	595B	B
JOHNSON & JOHNSON	-2.02%	367B	C+
MERCK & CO., INC.	+20.23%	334B	B-
ABBVIE INC.	+5.29%	289B	C+
ASTRAZENECA PLC	+14.77%	239B	B+
NOVARTIS AG	+9.13%	211B	B-
ROCHE HOLDING AG	-3.97%	203B	A+
AMGEN INC.	+9.34%	171B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality